Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Futura Medical ( (GB:FUM) ) has provided an update.
Futura Medical plc has announced the appointment of Alex Duggan as interim CEO, following board changes and the resignation of Angela Hildreth as Finance Director and COO. Duggan, with extensive leadership experience, will lead a strategic review of the company’s operations, focusing on the sales and marketing strategies for Eroxon, which has shown slower than expected sales momentum. The review aims to refine the company’s commercial plans and maximize value for stakeholders, with an update expected by late September.
The most recent analyst rating on (GB:FUM) stock is a Buy with a £140.00 price target. To see the full list of analyst forecasts on Futura Medical stock, see the GB:FUM Stock Forecast page.
More about Futura Medical
Futura Medical plc is a developer of innovative sexual health products, with a focus on topically delivered gel formulations. Their lead product, Eroxon, is a clinically proven topical gel for the treatment of Erectile Dysfunction (ED), offering a unique over-the-counter solution that works within ten minutes. Futura has established distribution partnerships in major markets, including the US and Europe, to address significant unmet needs in the ED market.
Average Trading Volume: 758,424
Technical Sentiment Signal: Sell
Current Market Cap: £36.6M
See more data about FUM stock on TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money